220
Participants
Start Date
June 30, 2023
Primary Completion Date
May 14, 2026
Study Completion Date
December 14, 2026
ART6043
ART6043 will be given orally.
Olaparib
Olaparib will be given orally.
Jefferson University Hospitals - Kimmel Cancer Center, Philadelphia
SCRI oncology partners, Nashville
South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids
Stephenson Cancer Center - Oncology, Oklahoma City
Mary Crowley Cancer Center - Clinic, Dallas
The University of Texas - MD Anderson Cancer Center, Houston
Memorial Sloan-Kettering Cancer Center (MSKCC), New York
Lead Sponsor
Artios Pharma Ltd
INDUSTRY